EC Paediatrics

Research Article Volume 10 Issue 9 - 2021

Evolutionary Aspects of Newborns Under 1500g Treated with Fluoroquinolones in Libreville, Gabon

Kuissi Kamgaing Eliane1,2*, S Minto’o Rogombe1, R Koumba Maniaga1,2, A Lembet Mikolo1,2, E Mintsa Mi Kama1,2, I Busugu Bu Mbadinga1,2 and S Ategbo1,2

1Department of Pediatrics, University of Health Sciences, BP, Libreville, Gabon
2Children Pole, Mother-Child Hospital-University Center Jeanne Ebori Foundation of Libreville, BP, Libreville, Gabon

*Corresponding Author: Kuissi Kamgaing Eliane, Professor, Department of Pediatrics, University of Health Sciences, BP, Libreville, Gabon.
Received: September 06, 2021; Published: September 18, 2021




Introduction: The resistance of germs responsible for neonatal infections sometimes requires the use of fluoroquinolones that are not indicated at this age. Our goal was to assess the short- and medium-term fate of newborns under 1500g treated with fluoroquinolone in Libreville.

Methodology: Case control study, over a period of 3 years (January 2015 - December 2018). The cases consisted of newborns under 1500g treated for neonatal infection with fluoroquinolones. Controls were newborns under 1500g treated for neonatal infection with other antibiotic families. The parameters studied were urea, creatinine, blood glucose of cases at Day0, Day10 and Day30 post-treatment. We compared anthropometric parameters and motor acquisition at 3, 6 and 12 months of the two groups.

Results: In the fluoroquinolones group, sepsis was the most observed localization (60%) and E. coli the most found germ (28%). The average time to the introduction of fluoroquinolones was 15d ± 7d. The most widely used molecule was Ciprofloxacin (68%). The most observed side effect was hypoglycaemia (28%) and an increase in serum creatinine (p = 0.006) and uremia (p = 0.0013) was observed on Day10 post-treatment. We did not observe any musculoskeletal manifestations. The evolution of anthropometric parameters and motor development was comparable in the 2 groups.

Conclusion: Fluoroquinolones motivated by the consideration of benefit/risk are well tolerated in newborns under 1500g.


Keywords: Low Weight Newborn; Fluoroquinolones; Libreville-Gabon

  1. Muylaert A and Mainil JG. “Résistances bactériennes aux antibiotiques: les mécanismes et leur « contagiosité”. Annales de Médecine Vétérinaire 156 (2012): 109-123.
  2. Brun-Buisson C., et al. “Résistance bactérienne aux antibiotiques: épidémiologie et prospective”. Science et Pseudo-Sciences Antibiotiques (2018): 325.
  3. Organisation mondiale de la santé. Plan d'action mondial sur la résistance aux antimicrobiens. OMS (2015).
  4. Organisation mondiale de la santé. Pourquoi un Défi mondial sur les infections nosocomiales. OMS (2020).
  5. Kuissi Kamgaing E., et al. “Epidemiological Aspects and Evolution of Nosocomial Infection in the Neonatology Unit of Angondje Teaching Hospital”. The Neonatal and Pediatric Medicine1 (2019): 182.
  6. Andrianarivelo AM., et al. “Profil bactériologique des infections néonatales à l’unité de réanimation néonatale de la Maternité de Befelatanana. Revue d’Anesthésie-Réanimation et de Médecine d’Urgence 2 (2010): 1-4.
  7. Zaidi AKM. “Hospital acquired néonatal infections in developing countries”. Lancet 365 (2005): 1175-1188.
  8. Chabni N., et al. “Facteurs de risque de l’infection nosocomiale au niveau du service de néonatologie polyvalente de l’établissement hospitalier spécialisé mère-enfant de Tlemcen à l’Ouest algérien, « étude cas-témoins”. Journal de Pédiatrie et de Puericulture 28 (2015): 71-79.
  9. Aujard Y and Bottineau MC. “Épidémiologie mondiale des infections néonatales”. In. Aujard Y, Elservier Masson. Infection néonatale: bactériennes, mycosique, parasitaires et virales. Paris (2015): 11-18.
  10. Chemsi M., et al. “Incidence des infections bacteriennes nosocomiales. Hôpital d’enfants Abderrahim Harouchi, CHU Ibn Rochd, Casablanca, Maroc”. Journal de Pédiatrie et de Puericulture1 (2013): 11-18.
  11. Jatsho J., et al. “Clinical and Bacteriological Profile of Neonatal Sepsis: A Prospective Hospital-Based Study”. International Journal of Pediatrics (2020).
  12. Hassuna NA., et al. “Extensively-Drug Resistant Klebsiella pneumoniae Recovered From Neonatal Sepsis Cases From a Major NICU in Egypt”. Frontiers in Microbiology 11 (2020): 1375.
  13. Dalal P., et al. “Bacteriological profile and antimicrobial sensitivity pattern in neonatal sepsis: a study from North India”. International Journal of Research in Medical Sciences 4 (2017): 1541-1545.
  14. Cottineau MC. “Infection néonatales dans les pays en voie de développement”. In. Aujard Y, Elservier Masson. Infection néonatale: bactériennes, mycosique, parasitaires et virales. Paris (2015): 204-223.
  15. Dutta S., et al. “Ciprofloxacin administration to very low birth weight babies has no effect on linear growth in infancy”. Journal of Tropical Pediatrics 52 (2006): 103-106.
  16. Kuissi Kamgaing E., et al. “Colonisation digestive par des germes nosocomiaux des nouveau-nés hospitalisés au CHU d’Angondjé: aspects épidémiologiques et facteurs de risqué”. Journal de Pédiatrie Et De Puériculture 30 (2017): 193-200.
  17. Chaudhari S., et al. “Safety profile of ciprofloxacin used for neonatal septicemia”. Indian Pediatrics 12 (2004): 1246-1251.
  18. Masoumi B., et al. “Safety Profile of Using Ciprofloxacin in Paediatrics: A Systematic Review and Meta-Analysis”. Journal of Pediatrics Review 3 (2019): 129-140.
  19. Larouche G. “Les quinolones: des années soixante à aujourd’hui”. Pharmactuel2 (2001): 40-46.
  20. Patel K and Goldman JL. “Safety Concerns Surrounding Quinolone Use in Children”. The Journal of Clinical Pharmacology9 (2016): 1060-1675.
  21. Jackson MA and Schutze G E. “AAP committee on infectious diseases. The Use of Systemic and Topical Fluoroquinolones”. Pediatrics5 (2016).
  22. Wang JG., et al. “Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children”. Medicine34 (2020).
  23. Forsythe CT and Ernst ME. “Do fluoroquinolones commonly cause arthropathy in children?”. Canadian Journal of Emergency Medicine6 (2007): 459-462.
  24. World Health Organization. Model List of Essential Medicines. 7th List for Children. WHO (2019).
  25. Maria Pacifici G and Marchini G. “Clinical Pharmacology of Ciprofloxacin in Neonates: Effects and Pharmacokinetics”. International Journal of Pediatrics6 (2017): 5023-5041.
  26. Zhao W., et al. “Population Pharmacokinetics of Ciprofloxacin in Neonates and Young Infants Less than Three Months of Age”. Antimicrobial Agents and Chemotherapy 11 (2014): 6572-6580.
  27. Oulmaati A., et al. “L’apport des quinolones en néonatologie (à propos de 21 cas)”. Journal De Pédiatrie Et De Puericulture 4 (2013): 193-197.
  28. Kaguelidou F., et al. “Ciprofloxacin Use in Neonates A Systematic Review of the Literature”. The Pediatric Infectious Disease Journal 2 (2011): 29-37.
  29. Adefurin A., et al. “Ciprofloxacin safety in paediatrics: a systematic review”. Archives of Disease in Childhood9 (2011): 874-880.
  30. Aggarwal P., et al. “Multiple dose pharmacokinetics of ciprofloxacin in preterm babies”. Indian Pediatrics10 (2004): 1001-1007.
  31. Aujard Y. “Posologie des anti-infectieux (antibiotiques, antifongiques, antiviraux)”. In. Aujard Y, Elservier Masson. Infection néonatale: bactériennes, mycosique, parasitaires et virales. Paris: (2015): 235-242.
  32. Kim Y., et al. “Real-world safety evaluation of musculoskeletal adverse events associated with Korean pediatric fluoroquinolone use: a nationwide longitudinal retrospective cohort study”. Scientific Reports (2019): 9.

Kuissi Kamgaing Elianel., et al. “Evolutionary Aspects of Newborns Under 1500g Treated with Fluoroquinolones in Libreville, Gabon”. EC Paediatrics 10.10 (2021): 55-62.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net